Spots Global Cancer Trial Database for Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
Official Title: An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Study ID: NCT00866528
Conditions
Study Description
Brief Summary: The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Chicago, Illinois, United States
GSK Investigational Site, Columbus, Ohio, United States
GSK Investigational Site, Sutton, Surrey, United Kingdom
GSK Investigational Site, Newcastle upon Tyne, , United Kingdom
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
